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Costello syndrome is characterized by mental retardation, loose skin, coarse face, skeletal deformations, cardio-
myopathy, and predisposition to numerous malignancies. The genetic origin of Costello syndrome has not yet been
defined. Using immunohistochemistry and metabolic labeling with [3H]-valine, we have established that cultured
skin fibroblasts obtained from patients with Costello syndrome did not assemble elastic fibers, despite an adequate
synthesis of tropoelastin and normal deposition of the microfibrillar scaffold. We found that impaired production
of elastic fibers by these fibroblasts is associated with a functional deficiency of the 67-kD elastin-binding protein
(EBP), which is normally required to chaperone tropoelastin through the secretory pathways and to its extracellular
assembly. Metabolic pulse labeling of the 67-kD EBP with radioactive serine and further chase of this tracer indicated
that both normal fibroblasts and fibroblasts from patients with Costello syndrome initially synthesized comparable
amounts of this protein; however, the fibroblasts from Costello syndrome patients quickly lost it into the conditioned
media. Because the normal association between EBP and tropoelastin can be disrupted on contact with galactosugar-
bearing moieties, and the fibroblasts from patients with Costello syndrome revealed an unusual accumulation of
chondroitin sulfate–bearing proteoglycans (CD44 and biglycan), we postulate that a chondroitin sulfate may be
responsible for shedding EBP from Costello cells and in turn for their impaired elastogenesis. This was further
supported by the fact that exposure to chondroitinase ABC, an enzyme capable of chondroitin sulfate degradation,
restored normal production of elastic fibers by fibroblasts from patients with Costello syndrome. We also present
evidence that loss of EBP from fibroblasts of Costello syndrome patients is associated with an unusually high rate
of cellular proliferation.
Introduction
In 1977, Costello described two unrelated children with
poor postnatal growth, mental retardation, curly hair,
coarse facies, loose skin, and nasal papillomata, sug-
gesting the existence of a previously undescribed syn-
drome of uncertain genetic etiology (Costello 1977). The
delineation of Costello syndrome (MIM 218040) as a
separate entity was further substantiated by the descrip-
tion of 130 other patients (for current review, see van
Eeghen et al. 1999). Numerous diagnoses—including cu-
tis laxa (Patton and Baraitser 1993; Davies and Hughes
1994a, 1994b; Vila Torres et al. 1994), Donohue and
Leprechaun syndromes, Berardinelli-type lipodystrophy
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(Zampino et al. 1993), Noonan or cardiofaciocutaneous
syndromes (Borochowitz et al. 1992; Teebi and Shaabani
1993; Wieczorek et al. 1997), and ectodermal dysplasias
(van Eeghen et al. 1999)—have been initially considered
in patients showing the clinical features of Costello
syndrome.
The natural history of Costello syndrome is charac-
terized by two distinct phases. The first phase is often
marked by polyhydramnios and increased birth weight
and is followed by the second phase, which includes
failure to thrive, severe short stature, mental retarda-
tion, and a distinctive appearance with craniofacial and
dermatologic findings resembling those observed in ly-
sosomal storage disorders (fig. 1). Affected individuals
may have a silent or clinically significant hypertrophic
cardiomyopathy, cardiac valve malformations, and dys-
rhythmia (Fukao et al. 1996; Siwik et al. 1998; Tomita
et al. 1998). Other manifestations of Costello syndrome
include soft skin with excess wrinkling over the dorsum
of the hands and deep creases on the palms and soles,
hyperextensibility of digits, generalized hyperpigmen-
tation, pigmented nevi, vascular birthmarks, acanthosis
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Figure 1 Photographs depicting one of our patients with Costello syndrome at 6 mo of age, whose fibroblasts were used in the presented
studies. A, sparse and curly hair, “coarse” face, depressed nasal bridge, bulbous and upturned nose, low-set ears, full cheeks, large tongue,
pouting lower lip, strabismus. B, deep palmar creases. C, plantar creases.
nigricans, and papillomata and other tumors that de-
velop at later ages (Say et al. 1993; Costello 1996; Kerr
et al. 1998; Philip and Sigaudy 1998; Suri and Garrett
1998; Feingold 1999; Franceschini et al. 1999). The
genetic basis of Costello syndrome is unknown; how-
ever, the occurrence of Costello syndrome in two fam-
ilies with affected siblings (Zampino et al. 1993) and
two consanguineous matings (Borochowitz et al. 1992)
suggested autosomal recessive inheritance or gonadal
mosaicism. In contrast, a review of 20 reported families
affected by Costello syndrome (Lurie 1994) indicated
that advanced paternal age (38 years) and paternal-
maternal age difference (7.36 years) is a factor im-
plicating sporadic autosomal dominant mutations in
this disease. There has been only one report of a chro-
mosomal translocation t(1,22) (q25, q11) in a girl with
Costello syndrome (Czeizel and Timar 1995), and a
single report of neurofibromatosis type 2 mapped to
22q12.2 (Suri and Garrett 1998) in another patient with
Costello syndrome.
There have only been a few reports defining the bi-
ochemical basis of this condition. Qualitative and quan-
titative histological analyses showed impaired elastin
deposition in the skin of children with Costello syn-
drome (Vila Torres et al. 1994). In fact, an abnormal
size, shape, and arrangement of elastic fibers in patients
with Costello syndrome resembled those described in
cutis laxa. Histopathologic studies of autopsy cases re-
vealed that impaired deposition of elastin also occurs
in the tongue, pharynx, larynx, and upper esophagus
of patients with Costello syndrome, and that elastic fi-
bers of the bronchi, alveoli, aorta, and coronary arteries
of these children are thinner than in normal patient
tissue specimens (Mori et al. 1996). Despite the fact
that some patients with Costello syndrome resemble
those with Williams syndrome, genetic analysis of the
cells of these patients did not reveal any deletion of the
elastin gene and showed normal expression of elastin
mRNA (Mori et al. 1996). This suggested that the ob-
served disruption of elastic fibers in tissues of patients
with Costello syndrome may be due to some posttran-
slational modifications of tropoelastin, to problems aris-
ing from its inadequate secretion and extracellular dep-
osition, or to both.
Insoluble elastin is composed of covalently cross-
linked polypeptide chains of tropoelastin, which con-
stitutes the major component of the extracellular elastic
fibers that provide tissues with the property of elastic
recoil. This elastin polymer is assembled along a scaffold
of 12-nm microfibrils composed of heterogeneous gly-
coproteins such as fibrillin type 1, fibrillin type 2, and
microfibril-associated glycoprotein (MAGP) (Mecham
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and Hauser 1991; Rosenbloom et al. 1993; Christiano
and Uitto 1994; Vrhowski and Weiss 1998; Debelle and
Tamburro 1999). It has been shown that a highly hy-
drophobic and nonglycosylated 68–72-kD tropoelastin
(produced by fibroblasts, smooth muscle cells, and
chondrocytes) is chaperoned through the intracellular
secretory pathways by the 67-kD elastin-binding pro-
tein (EBP) (Hinek et al. 1988, 1996; Hinek 1994, 1996;
Hinek and Rabinovitch 1994). The 67-kD EBP is an
enzymatically inactive spliced variant of b-galactosidase
(S-GAL) (Hinek et al. 1993; Privitera et al. 1998) that
binds to the repeating hydrophobic domains on elastin,
but may also bind to moieties containing b-galactosu-
gars through a separate “lectin-like” binding domain
(Mecham et al. 1991). Binding of b-galactosugar-bear-
ing moieties to the lectin domain of EBP causes con-
formational changes of the entire 67-kD protein, such
that it loses its affinity for elastin and separates from
the cell surface. This property of the EBP seems to be
particularly important in the process of elastic-fiber as-
sembly, because tropoelastin delivered to the cell surface
has to be released from its EBP chaperone. We have
proposed that an orderly release of tropoelastin occurs
on interaction of EBP with galactosugars, presumably
protruding from the microfibrillar glycoproteins that
provide the scaffold for growing elastic fibers (Hinek et
al. 1991; Hinek 1994, 1996). We have shown, however,
that a high pericellular concentration of free galacto-
sugar-bearing moieties, such as chondroitin sulfate or
dermatan sulfate glycosaminoglycans, may lead to a
premature release of tropoelastin from EBP and con-
sequent disruption of elastic fiber production (Hinek et
al. 1988, 1991, 1992, 1993; Hinek 1996).
Because disruption of elastic-fiber production may
arise either from low production of tropoelastin and
microfibrillar proteins (e.g., in Williams and Marfan
syndromes, respectively) or from their inadequate se-
cretion and extracellular assembly (Hurler syndrome),
the present study was aimed at assessing the major steps
of elastogenesis in fibroblasts derived from six children
with Costello syndrome and from three age-matched
normal children.
Our data indicate that fibroblasts from patients with
Costello syndrome produce normal levels of the soluble
tropoelastin and properly deposit an extracellular mi-
crofibrillar scaffold but are unable to assemble elastic
fibers, because of a secondary deficiency in EBP. We
suggest that abnormal accumulation of chondroitin sul-
fate–bearing moieties by fibroblasts from patients with
Costello syndrome may induce shedding of EBP from
the cell surface and prevent normal recycling of this
reusable tropoelastin chaperone. We also found an in-
creased rate of proliferation of fibroblasts from patients
with Costello syndrome, which could be influenced by
loss of EBP.
Material and Methods
Material
All chemical grade reagents and the monoclonal an-
tibody to chondroitin sulfate A were from Sigma. Alpha-
minimum essential medium (MEM), FCS, and other
cell-culture products were obtained from Gibco Life
Technologies. Insoluble elastin and the polyclonal an-
tibody to tropoelastin were purchased from Elastin
Products Co., Inc. Peanut agglutinin was purchased from
EY Laboratories. Microfibrillar proteins were detected
with a polyclonal antibody to MAGP and to human
fibrillin 1 from Elastin Products Co., Inc. Monoclonal
antibody to fibronectin (mAB1940) was from Chemicon
and polyclonal antifibronectin antibody was obtained
from ICN. Polyclonal antibody to human collagen type
I and to human biglycan (LF 39 and 112, respectively)
were a generous gift from L. W. Fisher of The National
Institutes of Health. Antibody-recognizing CD44 (Her-
mes-1) was obtained from Endogen. Fluorescein-con-
jugated antibodies, goat anti-rabbit (GAR-FITC) and
goat anti-mouse (GAM-FITC), were purchased from
Sigma. Horseradish peroxidase-conjugated goat anti-
rabbit antibody (GAR-HRP) used for western blotting
was from Bio-Rad. The chemiluminescence detection kit
and radiolabeled reagents, [3H]-valine, [3H]-serine,
[35S]-methionine, and [3H]-thymidine were purchased
from Amersham Canada Ltd.
Fibroblast Cultures
Six children ranging in age from 1 mo to 16 years
(7669, 9951, 10595, 12195, 12196, and 12368) were
given a diagnosis of Costello syndrome on the basis of
the presence of cardinal clinical features previously as-
cribed to this phenotype (Costello 1996; Johnson et al.
1998; van Eeghen et al. 1999). These features include
characteristic coarse facies and thick lips, mental retar-
dation, postnatal growth retardation, sparse and curly
hair, deep palmar and plantar creases, loose skin of the
hands and feet, hypertrophic cardiomyopathy and ar-
rhythmia, and papillomata and other tumors. Biopsies
of forearm skin from three patients with Costello syn-
drome (7669, 9951, and 10595) and from three normal
children of matching ages (4212, 3858, and 4184) were
used as the primary source of fibroblasts tested in im-
munohistochemical, biochemical, and cell proliferation
studies. Moreover, fibroblasts obtained from three other
patients with Costello syndrome (12195, 12196, and
12368) were analyzed by immunohistochemistry alone.
Fibroblasts were originally isolated by collagenase di-
gestion of the skin fragments and then passaged 2–6
times by trypsinization and maintained in alpha-MEM
supplemented with 20 mM Hepes, 1% antibiotics/an-
timycotics, and 10% fetal bovine serum (FBS).
862 Am. J. Hum. Genet. 66:859–872, 2000
Immunostaining
Subconfluent, 48-h cultures of normal and Costello
fibroblasts, fixed in cold 100% methanol at 20C for
30 min, were incubated with 10 mg/ml of polyclonal
antibody raised to the elastin/laminin-binding domain
of the alternatively spliced variant of b-galactosidase
(anti-S-GAL) (Hinek et al. 1993) and with the BCZ mon-
oclonal antibody, which recognizes a different epitope
on the EBP (Mecham et al. 1988). Parallel cultures fixed
for 10 min in 4% paraformaldehyde, with or without
detergent (0.2% Triton X-100) that permeabilizes cell
membranes, were treated with 10 mg/ml of monoclonal
antibody to chondroitin sulfate or with 10 mg/ml of an-
tibodies that recognize the chondroitin sulfate–bearing
proteoglycans biglycan and CD44.
In addition, the histochemical detection of galacto-
sugar-bearing glycoconjugates was also performed by
staining nonpermeabilized and permeabilized fibroblasts
with 0.1 mg/ml of fluorescein-conjugated peanut agglu-
tinin (FITC-PNA), which selectively binds to Galb1-
3GalNac domains (Zhou et al. 1999).
Ten-day-old cultures, containing abundant extracel-
lular matrix and fixed in cold 100% methanol, were
incubated with 20 mg/ml of polyclonal antibody to tro-
poelastin (Prosser et al. 1991), 2 mg/ml of monoclonal
antibody to fibronectin (Vartio et al. 1987), and 10 mg/
ml of polyclonal antibody to collagen type I. The parallel
cultures scheduled for immunohistochemical assessment
of microfibrillar components were fixed in 0.5% para-
formaldehyde for 15 min, were blocked in PBS contain-
ing 0.1 M ammonium chloride, were treated with spe-
cific 20 mg/ml of polyclonal antibody to fibrillin or
additionally pretreated for 10 min with PBS containing
50 mM DTT, were alkylated with 100 mM iodoaceta-
mide for 15 min, were washed in PBS, and then were
immunostained with specific polyclonal antibody to
MAGP at the same concentration. All cultures were in-
cubated with appropriate fluorescein-conjugated sec-
ondary antibodies (GAR-FITC or GAM-FITC) for an
additional hour. Nuclei were counterstained with pro-
pidium iodide.
Morphometric analysis of 10-d-old cultures immu-
nostained with antibodies recognizing extracellular ma-
trix components was performed by an Olympus AH-3
microscope attached to a CCD camera (Optronix) and
a computerized video analysis system (Image-Pro Plus
software 3.0 for Macintosh [Media Cybernetics]).
Tropoelastin and Insoluble Elastin Assays
Fibroblasts from normal patients and patients with
Costello syndrome were grown to confluency in 100-
mm dishes in quadruplicates. [3H]-valine (20 mCi) was
added to each dish along, with fresh media. Cultures
were then incubated for 72 h, and the soluble and in-
soluble elastin was assessed separately in each culture.
First, conditioned media was collected and immunopre-
cipitated with a polyclonal antibody to tropoelastin;
then, soluble proteins present in the intracellular com-
partments were extracted with 0.1 M acetic acid; and
then, intracellular tropoelastin was immunoprecipitated
from extracts and was assessed quantitatively by scin-
tillation counting, as described elsewhere (Hinek and
Rabinovitch 1994). The remaining cultures containing
cell remnants and deposited insoluble extracellular ma-
trix were scraped and boiled in 0.5 ml of 0.1 N NaOH
for 45 min to solubilize all matrix components except
elastin. The resulting pellets containing the insoluble
elastin were then solubilized by boiling in 200 ml of 5.7
N HCl for 1 h, and the aliquots were mixed with scin-
tillation fluid and were counted.
The integrity of tropoelastin produced by fibroblasts
from normal and Costello syndrome patients was also
assessed after confluent cultures (initially plated 5 #
106cells/dish) were pulsed with 15 mCi/ml [14C]-valine in
valine-free medium for 2 h. The intracellular tropoelastin
was then immunoprecipitated with specific antitropoe-
lastin antibody (Prosser et al. 1991) from the cell layer
extracts produced with 1% Nonidet P-40 in 50 mM TBS
pH 8 containing proteinase inhibitors (2 mM benza-
midine, 2 mM EACA, 2 mM PMSF, 1 mM EDTA, 2
mM leupeptin, and 1 mg/ml Trasylol) and analyzed by
SDS-PAGE followed by autoradiography and by western
immunoblotting.
Isolation of EBP
To compare patterns of the EBP expression by fibro-
blasts from normal children and those with Costello syn-
drome, we performed pulse-chase experiments. Fibro-
blasts were initially plated 1#106cells/dish to form a
subconfluent culture, incubated in triplicate in serum-
free Medium 199 for 6 h, and then pulsed with 15 mCi/
ml [14C]-serine in serine-free medium for 1 h. The cul-
tures were then rinsed well and chased in fresh Medium
199 for 5, 15, 30, and 45 min. At the end of each chase
period, the cell layers and the media were processed sep-
arately. To isolate the EBP, we used the standard elastin-
affinity chromatography technique as described else-
where (Hinek et al. 1993, Hinek and Wilson 2000). The
elastin-bound proteins released from elastin slurries were
resolved by 7.5%–12% SDS-PAGE followed by auto-
radiography. The identity of EBP was additionally con-
firmed by immunoblotting with affinity-purified anti-S-
Gal antibody recognizing 67-kD EBP, followed by GAR-
HRP conjugated secondary antibody and amplification
with the ECL chemiluminescence detection system. The
media from each culture was also mixed with a protease-
inhibitor cocktail and then subjected to immunoprecip-
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itation with 2 mg/ml of anti-S-Gal antibody (Privitera et
al. 1998).
Assessment of Fibroblast Proliferation
Fibroblasts from normal and Costello syndrome chil-
dren were suspended in alpha-MEM containing 10%
FBS and were initially plated in six-well dishes at a den-
sity of 50,000 cells per well. The medium was changed
24 h later, and parallel cultures were maintained for the
next 48 h in normal medium containing 10% FBS in
the presence or absence of insoluble elastin (1 mg/well).
Cell proliferation in 72 h–cultures were first assessed
with an inverted microscope with Nomarski optic, and
then cells were trypsinized and were counted in a hem-
ocytometer. Parallel sextuplicate cultures incubated with
the earlier-mentioned agents were also exposed to [3H]-
thymidine (2 mCi/well) for the last 24 h. These cultures
were then washed in PBS and treated with cold trich-
loroacetic acid twice for 10 min at 4C. For 30 min, 0.5
ml of 0.3 N NaOH was added to all dishes, and 200-
ml aliquots of each culture were then mixed with scin-
tillation fluid and counted. In all biochemical studies,
means and standard deviations were calculated, and sta-
tistical analyses were done by ANOVA.
Results
Comparison of 10-d-old fibroblast cultures immunos-
tained with antitropoelastin antibody revealed that—in
contrast to normal fibroblasts, which produced a dense
network of elastic fibers (fig. 2A)—the fibroblasts from
patients with Costello syndrome showed only intracel-
lular accumulation of the immunodetectable material
(fig. 2B). The lack of elastic fibers in cultures of fibro-
blasts from Costello syndrome patients contrasted with
the presence of normally assembled microfibrillar scaf-
folds containing the immunodetectable fibrillin type I
(fig. 2C, 2D). Moreover, the extracellular matrix pro-
duced by Costello fibroblasts was consistently found to
have higher-than-normal expression of collagen type I
(fig. 2F) and fibronectin (fig. 2H). Quantitative analysis
of immunostaining with matrix component–specific an-
tibodies revealed that this abnormal pattern of extra-
cellular matrix distribution was consistent in cultures of
fibroblasts derived from all six children with Costello
syndrome (fig. 3).
Quantitative assessment of [3H]-valine incorporation
into immunoprecipitatable soluble tropoelastin ex-
tracted jointly from the cell layers and from the con-
ditioned media showed that fibroblasts from patients
with Costello syndrome and fibroblasts from normal
children synthesized comparable amounts of tropoelas-
tin (fig. 4A). The separate immunoprecipitation of met-
abolically labeled tropoelastin from the cell-layer ex-
tracts and from the conditioned media clearly indicated
that fibroblasts from patients with Costello syndrome
were characterized by an impaired secretion of newly
synthesized tropoelastin. In contrast to cultures of nor-
mal fibroblasts, in which cellular extracts contained
only a small portion of total [3H]-valine-labeled tro-
poelastin, the cell-layer fractions of fibroblasts from pa-
tients with Costello syndrome retained the majority of
the metabolically labeled tropoelastin. Consistently, fi-
broblasts from patients with Costello syndrome incor-
porated much less radioactive valine into the NaOH-
insoluble elastin than did their counterparts taken from
normal children. Moreover, SDS-PAGE and autora-
diography of metabolically radiolabeled proteins im-
munoprecipitated with antitropoelastin antibody indi-
cated that the bulk of soluble tropoelastin extracted
from the fibroblasts of patients with Costello syndrome
was partially degraded. Whereas cell extracts from nor-
mal children contained significant amounts of radiola-
beled 70-kD tropoelastin, the cell-layer extracts of fi-
broblasts from patients with Costello syndrome showed
3–5 times lower levels of the intact 70-kD tropoelastin
(as measured by densitometry) and showed numerous
species of lower molecular weight, representing tropoe-
lastin degradation products (fig. 4B).
Immunostaining with anti-S-GAL antibody (which
recognizes the elastin-binding domain of EBP) and BCZ
antibody (which recognizes a different epitope on EBP)
consistently indicated that the levels of this protein were
greatly diminished in fibroblasts from patients with Cos-
tello syndrome. As depicted in figure 5A, EBP (detected
with anti-S-GAL antibody) was particularly well ex-
pressed on the surface of normal fibroblasts. In contrast,
the fibroblasts from patients with Costello syndrome
showed only negligible cell surface immunostaining (fig.
5B).
Another striking difference between normal fibro-
blasts and fibroblasts from patients with Costello syn-
drome was their expression of the epitope detected with
the monoclonal antibody raised to chondroitin sulfate
A. Immunostaining of nonpermeabilized cells showed
that, in contrast to normal fibroblasts that deposited
chondroitin sulfate extracellularly (fig. 5C), the fibro-
blasts from patients with Costello syndrome were spot-
ted with large amounts of immunogenic materials, likely
representing accumulations of chondroitin sulfate–
containing proteoglycans on their surface (fig. 5D). Im-
munostaining of permeabilized cultures indicated that,
in addition to extracellular matrix, the normal fibro-
blasts showed the presence of chondroitin sulfate epi-
topes only in perinuclear regions (fig. 5E). Permeabilized
fibroblasts from patients with Costello syndrome
revealed accumulation of the chondroitin sulfate–
containing material in multiple cytoplasmic vesicles (fig.
5F). Immunostaining of parallel cultures with antibody
Figure 2 Representative photomicrographs of 10-d-old cultures immunostained with antitropoelastin antibody indicate that normal
fibroblasts (A) produced long, branching elastic fibers, whereas fibroblasts from patient with Costello syndrome (B) did not deposit any
extracellular elastin. Deposition of fibrillin I by Costello fibroblasts (C) does not differ from normal fibroblasts (D). Costello fibroblasts, however,
deposit more collagen type 1 (F) and fibronectin (H) than do normal fibroblasts (E and G, respectively). Whereas Costello fibroblasts cultured
for 10 d in normal medium did not display any extracellular elastic fibers (I), treatment with chondroitinase ABC (J) restored their ability to
deposit elastic fibers in the extracellular matrix.
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Figure 3 Morphometric analysis of extracellular matrix (ECM)
components immunostained with specific antibodies in 10-d-old cul-
tures of normal and Costello fibroblasts. Fibroblasts from patients with
Costello syndrome deposit only negligible amounts of immunodetect-
able extracellular elastin. Amounts of fibronectin and collagen type I
produced by Costello fibroblasts significantly exceed those present in
cultures of normal fibroblasts, whereas deposition of fibrillin I and
MAGP by Costello fibroblasts does not differ from normal fibroblasts.
In each analyzed group, 50 low-power fields (´20) from three separate
cultures (per independent patients) were analyzed and the area oc-
cupied by the particular immunodetectable component quantified. The
abundance of each component was then expressed as a percentage of
the entire analyzed field (mean  SD), and results from cultures of
Costello fibroblasts were statistically compared with those in cultures
of normal skin fibroblasts ( ).P ! .001
Figure 4 A, Quantitative analysis of [3H]-valine-labeled im-
munoprecipitatable tropoelastin indicates that both normal (3858,
4184, and 4212) and Costello fibroblasts (7669, 9951, and 10595)
synthesize comparable amounts of total metabolically labeled tropoe-
lastin. In contrast to normal fibroblasts, Costello fibroblasts retain the
majority of their metabolically labeled tropoelastin intracellularly.
Consistently, Costello fibroblasts incorporate much less [3H]-valine
into extracellular insoluble elastin than do normal fibroblasts. B, Rep-
resentative autoradiographs of metabolically radiolabeled proteins im-
munoprecipitated with antitropoelastin antibody from the cell-layer
extracts. In contrast to normal fibroblasts (3858, 4184, and 4212) that
contain a significant amount of radiolabeled 70-kD tropoelastin, the
Costello fibroblasts (7669, 9951, and 10595) show much lower levels
of intact 70-kD tropoelastin and show numerous lower molecular
weight species that likely represent tropoelastin degradation products.
to the a subunit of hexosaminidase (data not shown)
indicated that most of these chondroitin sulfate–positive
vesicles could be identified as lysosomes. Interestingly,
histochemistry with peanut agglutinin, which selectively
binds to Galb1-3GalNac domains, showed identical
patterns of cell surface and intracellular localization as
anti–chondroitin sulfate antibodies (data not shown).
Additional immunochemical studies aimed at the pos-
itive identification of the chondroitin sulfate–bearing
moieties accumulating in fibroblasts from patients with
Costello syndrome indicated that their intracellular ves-
icles (lysosomes) were also immunoreactive to antibod-
ies recognizing the protein components of the chondro-
itin sulfate–bearing proteoglycans, CD44 (fig. 5H) and
biglycan (fig. 5J). In contrast to fibroblasts from patients
with Costello syndrome, normal fibroblasts did not re-
veal any storage of CD44 (fig. 5G) or biglycan (fig. 5I).
Immunostaining of nonpermeabilized cells with these
antibodies also showed a cell-surface aggregation of
such moieties on the cell surfaces of fibroblasts from
patients with Costello syndrome, but not on normal
fibroblasts (data not shown).
The metabolic pulse-chase labeling of EBP followed
by the chase indicated that both types of fibroblasts
initially synthesized similar amounts of this protein. In
contrast to normal fibroblasts, which showed only a
small decrease in labeled EBP during the chase period,
the amounts of EBP extractable from fibroblasts of pa-
tients with Costello syndrome steadily decreased during
the 45-min chase. The autoradiography did not detect
any degradation products of EBP in the cell extracts
from patients with Costello syndrome (fig. 6), and this
metabolically labeled protein could be immunoprecip-
itated in increased amounts from the respective condi-
tioned media during the chase, suggesting extensive
Figure 5 A–D, Representative photomicrographs of 48-h-old cultures of lightly fixed and nonpermeabilized fibroblasts. Immunostaining
with anti-S-Gal antibody, which recognizes EBP, indicates that normal fibroblasts (A) show strong cell-surface expression of this protein, whereas
Costello fibroblasts (B) show greatly diminished levels of the EBP. Immunostaining with monoclonal antibody recognizing chondroitin sulfate
A indicates that, in contrast to cultures of normal fibroblasts (C), which show immunodetectable epitope only in the extracellular matrix,
Costello fibroblasts show strong cell surface–associated expression of chondroitin sulfate (D). E–J, Representative photomicrographs of 48-h-
old cultures of permeabilized fibroblasts immunostained with antibodies to chondroitin sulfate A epitope (E, F) to CD44 (G, H) and to biglycan
(I, J). In contrast to normal fibroblasts (E, G, I), which do not show any intracellular immunostaining with anti-CD44 and antibiglycan
antibodies, and only perinuclear localization of the chondroitin sulfate epitope, Costello fibroblasts (F, H, J) show strong and overlapping
intracellular (lysosomal) localization of all three epitopes.
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Figure 6 Representative autoradiographs (upper panel) showing
levels of the 67-kD EBP during the chase after metabolic pulse labeling
with radioactive serine. Results indicate that both normal and Costello
fibroblasts initially synthesize comparable amounts of EBP, isolated by
elastin affinity columns. In contrast to normal fibroblasts, which retain
the majority of the labeled EBP, Costello fibroblasts steadily lose this
newly produced protein, which can be immunoprecipitated in in-
creased amounts from the respective conditioned media during the
chase (lower panel) .
shedding of EBP molecules from the cell surface of fi-
broblasts from patients with Costello syndrome.
Because the results mentioned earlier strongly indi-
cated that impaired elastic-fiber assembly in cultures of
Costello fibroblasts coincides with accumulation of the
immunodetectable chondroitin sulfate–bearing moie-
ties, which induce shedding of EBP (Hinek et al. 1988,
1991), we decided to test whether enzymatic removal
of these galactosugar-bearing moieties from the cell sur-
face would improve elastogenesis. Indeed, treatment of
Costello syndrome–fibroblast cultures with an enzyme
that degrades chondroitin sulfates (chondroitinase ABC,
0.1 U/ml/day, for 10 d) led to restoration of normal
elastic-fiber assembly (fig. 2I, J).
We have established, in addition to the results men-
tioned earlier, that the growth rate of cultured fibro-
blasts from patients with Costello syndrome was higher
than that of normal fibroblasts. The striking difference
in the cell density between normal and Costello fibro-
blasts was clearly noticeable in 3-d-old cultures (fig.
7A). Whereas normal fibroblasts initially plated at con-
centrations of 50,000 cells/well grew to an average
140,000 cells/well in the 3 d, the fibroblasts from pa-
tients with Costello syndrome plated at the same initial
density reached 320,000 cells/well (fig. 7B). Similar re-
sults indicating an increased rate of proliferation in
cultures of fibroblasts from patients with Costello
syndrome were obtained when incorporation of
[3H]-thymidine was assessed (fig. 7C). Interestingly, ad-
dition of exogenous insoluble elastin to cultures of fi-
broblasts derived from patients with Costello syndrome
significantly decreased their proliferation as assessed by
inverted microscopy, direct cell counting, and incor-
poration of [3H]-thymidine (fig. 7A, B, C ). Exogenous
insoluble elastin not only caused inhibition of cell
growth but also induced changes in the cell shape. Al-
though some Costello cells that did not maintain direct
contact with clusters of insoluble elastin remained elon-
gated, cells attached to elastin clusters were spread and
resembled normal fibroblasts. It should also be men-
tioned that virtually all fibroblasts maintaining direct
contact with insoluble elastin did not display bromo-
deoxyuridine incorporation or positive staining with Ki-
67 antibody (data not shown). Treatment with insoluble
elastin did not affect the growth rate of normal
fibroblasts.
Discussion
Although the basic genetic defect in Costello syndrome
remains obscure, the cardinal phenotypic features ob-
served in patients with Costello syndrome indicate that
pathology of mesenchyme-derived tissues may constitute
fundamental problems in this clinical entity. Findings of
defective elastic fibers in tissue samples from patients
with Costello syndrome (Vila Torres et al. 1994; Mori
et al. 1996) reinforced this suggestion and focused our
studies on the pathomechanism of impaired elastoge-
nesis in Costello syndrome.
Results of our immunocytochemical and metabolic
studies indicated that Costello fibroblasts showed a nor-
mal rate of tropoelastin production but were unable to
secrete tropoelastin or to assemble extracellular insol-
uble elastin. The coincident finding of a very low im-
munosignal for EBP in Costello cells initially suggested
a deficiency in this recyclable tropoelastin chaperone
(Hinek et al. 1988, 1996; Hinek and Rabinovitch 1994)
as a factor for the disruption of elastic-fiber formation
in Costello syndrome. The pulse-chase experiments in-
dicated, however, that fibroblasts from both normal pa-
tients and patients with Costello syndrome initially pro-
duced equal amounts of the metabolically labeled 67-kD
EBP, but only Costello fibroblasts quickly lost it into
the conditioned media. We therefore propose that EBP
was rapidly shed from the Costello fibroblast. Because
immunocytochemistry detected accumulation of the
chondroitin sulfate–bearing moieties in Costello fibro-
blasts, we additionally suggest that shedding of EBP
may occur on contact of this protein with cell-surface
chondroitin-sulfate moieties. This conclusion is based
on our previous observations (1) that binding of gal-
actosugar-containing moieties to the galactolectin do-
main of the EBP induces structural changes of this pro-
tein that make it unable to associate with tropoelastin
and with the cell membranes (Hinek et al. 1988, 1993)
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Figure 7 A, Representative phase-contrast micrographs of 3-d-old cultures illustrating that the growth rate of fibroblasts from patients
with Costello syndrome (middle panel) were considerably higher than those taken from normal children (left panel). Addition of insoluble
elastin to cultures of Costello fibroblasts substantially reduced their cell density (right panel). Arrows indicate clusters of insoluble elastin attached
to the cultured fibroblast. B, Cell counting and C, incorporation of [3H]-thymidine also show the increased growth rate of Costello fibroblasts
(blackened bars) as compared with normal fibroblasts (unblackened bars) in 3-d-old cultures. These assays also illustrate that high proliferation
of Costello fibroblasts was significantly reduced in cultures treated with exogenous insoluble elastin (striated bars). Treatment with insoluble
elastin did not change the proliferative rate of normal fibroblasts. D, Parallel cultures of normal fibroblasts treated with chondroitin sulfate
(CS) or dermatan sulfate (DS), but not heparan sulfate (HS) (all in concentration 400 mg/ml), significantly increased the rate of their [3H]-
thymidine incorporation. At the same time, addition of chondroitinase ABC (0.2 U/d) (Chnase ABC) significantly decreased incorporation of
[3H]-thymidine in cultures of fibroblasts taken from patients with Costello syndrome. In all experiments, cells were plated with the same initial
density of 50,000 cells/well. Values of mean  SD from three different experiments were statistically compared with untreated controls within
the same cell type ( ).P ! .002
and (2) that addition of exogenous galactosugar-bearing
moieties (chondroitin sulfate or dermatan sulfate) to
cultures of normal fibroblasts, chondroblasts, and
smooth-muscle cells caused depletion of EBP and dis-
ruption of elastic-fiber production (Hinek et al. 1991,
1992). Decreased deposition of insoluble elastin by rat-
lung fibroblasts cultured in the presence of galactos-
amine-containing chondroitin sulfate and dermatan sul-
fate has also been reported by McGowan et al. (1993).
Despite the fact that extracts of fibroblasts from patients
with Costello syndrome revealed the presence of de-
graded tropoelastin, cultures of these fibroblasts did not
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show any higher-than-normal activity of secretable elas-
tolytic enzymes that could degrade exogenous insoluble
elastin substrate (data not shown). Thus, impaired for-
mation of extracellular fibers—but not their accelerated
degradation—is likely responsible for the low net con-
tent of insoluble elastin in the tissues of Costello pa-
tients. In fact, increased elastolysis would not be ex-
pected because chondroitin sulfate can sequestrate and
inactivate leukocytic elastase (Volpi 1997; Ying et al.
1997).
Our proposal that the impaired elastogenesis ob-
served in cells from patients with Costello syndrome
may be triggered by the accumulation of chondroitin
sulfate–bearing moieties was reinforced by the fact that
enzymatic degradation of these moieties by exogenous
chondroitinase ABC led to restoration of normal elastic-
fiber assembly. It should be also mentioned that results
of our present study, indicating links between impaired
elastogenesis in Costello syndrome and functional de-
ficiency of EBP induced by chondroitin sulfate–bearing
moieties, are consistent with our recent data of a very
similar effect in Hurler disease in which an accumula-
tion of dermatan sulfate (another galactosugar-bearing
glycosaminoglycan) is associated with impaired elas-
togenesis (Hinek and Wilson 2000). Existence of phe-
notypic similarities between patients with Costello
syndrome, with Hurler disease, and with other muco-
polysaccharidoses (Belcher 1972; Schieken et al. 1975;
Johnson et al. 1981; Haust 1987; Hopwood and Morris
1990; Nelson et al. 1990; Vinallonga et al. 1992; Neu-
feld and Muenzer 1997) may encourage future studies
aimed at elucidation of the primary genetic defect in
Costello syndrome. The objective would be to question
whether Costello syndrome might belong to the group
of metabolic-storage diseases (mucopolysaccharidoses)
caused by a primary deficiency in enzymes responsible
for degradation of chondroitin sulfate moieties. Our
finding that permeabilized Costello fibroblasts display
an apparent accumulation of the chondroitin sulfate-
bearing proteoglycans (CD44 and biglycan), in multiple
cytoplasmic vesicles that overlap with immunolocali-
zation of the lysosomal enzyme hexosaminidase, further
supports this claim. We suggest that Costello syndrome
cells (similar to known mucopolysaccharidoses) are not
capable of normal degradation of the chondroitin sul-
fate attached to several different compounds, and that
this inability may result in a storage of undegraded pro-
teoglycans (CD44, biglycan, and others) in lysosomes.
We speculate that a lack of a proper enzymatic degra-
dation of chondroitin sulfate components of these pro-
teoglycans may obscure their proteinase-binding do-
mains and consequently may prevent further degra-
dation of their protein cores.
Elastin is often thought to be a component produced
in the latest stages of fetal development and in the per-
inatal period (Cleary et al. 1967; Mecham and Hauser
1991; Rosenbloom et al. 1993; Pasquali-Ronchetti and
Baccarani-Contri 1997). Recent studies with the devel-
oping chick embryo, by means of in situ hybridization
techniques, revealed that tropoelastin mRNA is ex-
pressed early during development (Selmin et al. 1991;
Holzenberger et al. 1993). Studies by Hurle et al. (1994)
also showed the presence of elastic fibers during early
morphogenesis of the limb skeleton, in vivo and in vitro,
and suggested that the elastic-fiber scaffold plays an
important role in coordinating the size and the spatial
location of the cartilaginous skeletal elements within the
limb buds. They also observed precise patterns of elas-
tic-fiber arrangement present in the outflow tract and
atrioventricular cushion tissue of the heart, the early
developing lung, the notochord, and the somites. These
observations pointed to previously unsuspected func-
tions for elastic matrices during embryonic development
and substantiated our hypothesis that impaired elas-
togenesis in the developing skeleton, heart, or skin may
be play an important role in the overall pathophysiology
of the Costello syndrome.
Our observation that fibroblasts from patients with
Costello syndrome, which are unable to assemble nor-
mal elastic fibers, displayed an increased rate of prolif-
eration, as compared with normal skin fibroblasts, in-
dicates a potential pathophysiological link between the
absence of insoluble elastin and increased cell prolif-
eration. Further support for this link comes from a re-
cent observation of Li et al. (1998), who showed that
newborn transgenic mice lacking elastin protein die as
a result of arterial blockage with abnormal intimal
thickenings composed of proliferating smooth-muscle
cells. The possibility that insoluble elastin may, in fact,
negatively modulate mitogenic signals is further sub-
stantiated by the fact that administration of exogenous
insoluble elastin to cultured Costello fibroblasts nor-
malized their proliferation rate. Increased cellular pro-
liferation associated with decreased insoluble elastin in
extracellular matrix produced by Costello fibroblasts
may result from several overlapping mechanisms. First,
large hydrophobic particles of exogenous insoluble elas-
tin may attract soluble tropoelastin-derived peptides
present in the conditioned media and cause their pre-
cipitation (coacervation). Such a depletion of soluble
fragments of tropoelastin, known to be stimulators of
cell-cycle progression (Jung et al. 1998; Hinek et al.
1999) may therefore downregulate cellular prolifera-
tion. Second, establishment of physical contact between
large particles of insoluble elastin and the cell surface
may cause binding and trapping of EBP molecules that
prevent their shedding. Aggregation of cell-surface EBP
may, in turn, lead to masking of adjacent growth factor
receptors that normally transduce mitogenic signals in-
duced by serum-derived growth factors. Conversely, ex-
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tensive chondroitin sulfate–induced shedding of EBP
from the cell surface of Costello fibroblasts may lead to
unmasking of adjacent cell-surface receptors important
for mitogenic signal transduction. This suggestion is
consistent with our previously reported results showing
that chondroitin sulfate–dependent shedding of EBP
from cell surfaces of arterial smooth muscle cells un-
masks their adjacent interleukin type I receptors inter-
acting with IL-1b and facilitates cellular response to this
cytokine (Hinek et al. 1996), resulting in a net increase
in fibronectin production (also noted in cultures of Cos-
tello fibroblasts) and stimulation of cell migration and
proliferation. This proposed mechanism does not pre-
clude the possibility that chondroitin sulfate–containing
proteoglycans accumulating on the surface of fibro-
blasts from patients with Costello syndrome may also
act as coreceptors for major growth factors (e.g., bFGF).
In this regard, our finding of increased expression of
CD44 in fibroblasts from patients with Costello syn-
drome may be of special interest. This cell-surface
hyaluronate receptor containing a chondroitin sulfate
moiety, which may act as a low-affinity fibroblast
growth-factor receptor, has been widely implicated in
the growth of numerous human tumors (Borland et al.
1998; Herrlich et al. 1998; Ponta et al. 1998; Sneath
and Mangham 1998; Chiu et al. 1999; Humphrey et
al. 1999) including rhabdomyosarcoma, which has been
reported in patients with Costello syndrome (Kerr et al.
1998; Feingold 1999).
In summary, we propose that chondroitin sulfate–
dependent shedding of EBP from fibroblasts of patients
with Costello syndrome eventually eliminates recycling
of this tropoelastin chaperone and consequently dis-
rupts tropoelastin secretion and extracellular assembly
into elastic fibers. Thus, Costello syndrome should be
added to the list of inherited diseases that are charac-
terized by impaired elastogenesis. We also believe that
lack of insoluble elastin coincident with high rates of
cell proliferation may be relevant to the pathophysiol-
ogical mechanisms responsible for the development of
the cardinal phenotypic features of Costello syndrome,
including skeletal, cardiovascular, and skin problems,
as well as the development of benign and malignant
tumors.
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